Research graph
References from Anticoagulation Treatment Response Among Phenotypic <scp>ESUS</scp> Clusters: Evidence From <scp>CASPR</scp>. Local targets link to admitted publications; unresolved targets remain external evidence.
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
10.1161/str.0000000000000375 · 2021 · External reference
Unresolved reference
External reference
Robust Estimation of Heterogeneous Treatment Effects: An Algorithm‐Based Approach
10.1080/03610918.2021.1974883 · 2023 · External reference
Unresolved reference
External reference
Review and Update of the Concept of Embolic Stroke of Undetermined Source
10.1038/s41582-022-00663-4 · 2022 · External reference
Tailoring the Approach to Embolic Stroke of Undetermined Source: A Review
10.1001/jamaneurol.2019.0591 · 2019 · External reference
Unique Clinicopathologic Subclassifiers of Cryptogenic Cerebral Emboli
10.1016/j.jstrokecerebrovasdis.2022.106427 · 2022 · External reference
Apixaban Versus Aspirin for Embolic Stroke of Undetermined Source
2024 · External reference
Rivaroxaban for Stroke Prevention After Embolic Stroke of Undetermined Source
10.1056/nejmoa1802686 · 2018 · External reference
Dabigatran for Prevention of Stroke After Embolic Stroke of Undetermined Source
10.1056/nejmoa1813959 · 2019 · External reference
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial
10.1001/jama.2023.27188 · 2024 · External reference
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial
10.1001/jamaneurol.2021.3828 · 2021 · External reference
Apixaban and Recurrent Stroke Risk With Left Ventricular Dysfunction: A Secondary Analysis of the ARCADIA Trial
10.1161/strokeaha.125.052724 · 2025 · External reference
Rivaroxaban or Aspirin for Patent Foramen Ovale and Embolic Stroke of Undetermined Source: A Prespecified Subgroup Analysis From the NAVIGATE ESUS Trial
10.1016/s1474-4422(18)30319-3 · 2018 · External reference
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
10.1136/bmj.39335.541782.ad · 2007 · External reference
Outcomes of Patients With Embolic Stroke of Undetermined Source Treated With Antiplatelet Agents or Anticoagulation
10.1212/wnl.0000000000213876 · 2025 · External reference
Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of Major Bleeding in Clinical Investigations of Antihemostatic Medicinal Products in Non‐Surgical Patients
10.1111/j.1538-7836.2005.01204.x · 2005 · External reference
Hypercoagulability and Mortality of Patients With Stroke and Active Cancer: The OASIS‐CANCER Study
10.5853/jos.2016.00570 · 2016 · External reference
Generalized Random Forests
10.1214/18-aos1709 · 2019 · External reference
10.1161/strokeaha.125.053755
10.1161/strokeaha.125.053755 · External reference
Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke: A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial
10.1001/jamaneurol.2024.2404 · 2024 · External reference
Rivaroxaban Versus Aspirin for Secondary Prevention of Ischaemic Stroke in Patients With Cancer: A Subgroup Analysis of the NAVIGATE ESUS Randomized Trial
10.1111/ene.14172 · 2020 · External reference
Classification and Management of Ischemic Stroke in Patients With Active Cancer: A Scientific Statement From the American Heart Association
2026 · External reference
